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Human cytomegalovirus (HCMV) infection promotes the differentiation and persistent 
expansion of a mature NK cell subset, which displays high surface levels of the acti-
vating CD94/NKG2C NK cell receptor, together with additional distinctive phenotypic 
and functional features. The mechanisms underlying the development of adaptive 
NK cells remain uncertain but some observations support the involvement of a cog-
nate interaction of CD94/NKG2C with ligand(s) displayed by HCMV-infected cells. 
To approach this issue, the heterodimer and its adaptor (DAP12) were expressed 
in the human Jurkat leukemia T cell line; signaling was detected by transfection of 
a reporter plasmid encoding for Luciferase (Luc) under NFAT/AP1-dependent con-
trol. Engagement of the receptor by solid-phase bound CD94- or NKG2C-specific 
monoclonal antibodies (mAbs) triggered Luc expression. Moreover, reporter activation 
was detectable upon interaction with HLA-E+ 721.221 (.221-AEH) cells, as well as 
with 721.221 cells incubated with synthetic peptides, which stabilized surface expres-
sion of endogenous HLA-E; the response was specifically antagonized by soluble 
NKG2C- and HLA-E-specific mAbs. By contrast, activation of Jurkat-NKG2C+ was 
undetectable upon interaction with Human Fetal Foreskin Fibroblasts (HFFF) infected 
with HCMV laboratory strains (i.e., AD169, Towne), regardless of their differential ability 
to preserve surface HLA-E expression. On the other hand, infection with two clinical 
isolates or with the endotheliotropic TB40/E strain triggered Jurkat-NKG2C+ activa-
tion; yet, this response was not inhibited by blocking mAbs and was independent of 
CD94/NKG2C expression. The results are discussed in the framework of previous 
observations supporting the hypothetical existence of specific ligand(s) for CD94/
NKG2C in HCMV-infected cells.
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inTrODUcTiOn
Inhibitory receptors specific for MHC class I molecules with 
immunoreceptor tyrosine-based inhibitory motifs play a key 
role in preventing NK cell responses against normal autologous 
cells. This function is mainly fulfilled by members of the human 
killer-cell immunoglobulin-like receptor (KIR) family, which 
recognize sets of classical HLA class I (HLA-I) molecules, and 
by the CD94/NKG2A lectin-like heterodimer specific for HLA-
E. Conversely, other KIRs and CD94/NKG2C, which display a 
lower affinity for HLA-I ligands trigger protein tyrosine kinase 
pathways through DAP12, an adaptor with immunoreceptor 
tyrosine-based activation motifs. Similar inhibitory and activat-
ing NK  cell receptors (NKR) have been identified among the 
murine Ly49 and NKG2 lectin-like receptor families (1, 2). The 
hypothesis that MHC-specific activating NKR may contribute 
to the innate response against pathogens was supported by the 
evidence that Ly49H specifically interacts with the MHC class 
I-related murine cytomegalovirus glycoprotein m157, triggering 
NK cell effector functions and the development of a memory-
like response that confers resistance against the viral infection 
in some mice strains (3–5).
With this remarkable exception, no formal proof has been 
thus far obtained supporting the involvement of other activating 
KIR, NKG2, or Ly49 receptors in direct recognition of pathogen 
molecules (6). In this regard, human cytomegalovirus (HCMV) 
infection has been shown to promote the differentiation and 
persistent expansion of a mature NK  cell subset, which dis-
plays high surface levels of the activating CD94/NKG2C NKR 
(NKG2Cbright), together with additional distinctive phenotypic 
and functional features (7–12). The magnitude of such adaptive 
NK cell subset redistribution appears variable in healthy blood 
donors, being undetectable in some HCMV+ individuals. This 
NK  cell response pattern has been as well observed following 
active HCMV infection in newborns and immunocompromised 
patients (13–17). Although expansions of NKG2C+ NK  cells 
have been reported in the context of other infections (18–21), 
the effect appears restricted to individuals coinfected by HCMV, 
thus suggesting that it is specifically induced by this herpes virus, 
being potentially amplified along the immune response to other 
pathogens.
The mechanisms underlying differentiation and expansion of 
NKG2Cbright NK cells remain uncertain. Engagement of CD94/
NKG2C by specific monoclonal antibodies (mAbs) or HLA-E, 
expressed in the 721.221 (.221) HLA-I defective cell line, trig-
gered NKG2C+ NK-cell effector functions and proliferation in 
response to IL-2 or IL-15, strongly suggesting that the receptor 
might play a direct role in the response to HCMV infection 
(22, 23). In vitro proliferation of NKG2C+ cells was observed 
coculturing PBMCs or purified NK cells from some HCMV+ 
donors with HCMV-infected fibroblasts. The response required 
the participation of cytokines (i.e., IL-12, IL-15) and was 
antagonized by anti-CD94 (22), -NKG2C, or -HLA-E mAbs (23). 
These observations supported the hypothesis of an instructive 
process driven by a cognate interaction of the CD94/NKG2C 
receptor with ligand(s) displayed by HCMV-infected cells (24). 
Paradoxically, no formal evidence has been obtained supporting 
an active role of the CD94/NKG2C receptor in triggering 
in vitro NK cell effector functions against HCMV-infected cells, 
suggesting that NKG2C-mediated NK  cell activation might 
be hampered by viral immune evasion mechanism(s) (25). By 
contrast, antibody-dependent stimulation via CD16 (FcγR-IIIA) 
efficiently activates adaptive NKG2C+ NK  cells to mediate 
specific cytotoxicity, cytokine production, and proliferation in 
response to HCMV- and other virus-infected cells (26–29). CD2 
has been shown to play an important co-stimulatory role in anti-
body-dependent activation of NKG2C+ cells (30, 31). Recently, 
increased baseline proportions of adaptive NKG2C+ NK cells 
in kidney transplant recipients have been directly related with a 
reduced incidence of posttransplant HCMV infection (32), sug-
gesting that they may play a role in antiviral defense, involving 
CD94/NKG2C and/or CD16-dependent activation (33).
Previous reports revealed that binding of HLA-E to a 
peptide from the HCMV UL40 leader sequence preserves 
its expression in infected cells, engaging the CD94/NKG2A 
inhibitory receptor (34, 35). On the other hand, viral MHC 
class I-modulating molecules (i.e., US2-US11) were shown 
to play a prevalent role in governing the response of NK cells 
against infected targets (36).
In the present study, we approached the identification of 
putative ligand(s) for CD94/NKG2C in HCMV-infected cells, 
reducing the complexity of NK cell-infected target interactions. 
To this end, both receptor subunits and DAP12 were stably 
expressed in the human Jurkat leukemia T cell line. Signaling 
was detected by transient transfection of a reporter plasmid 
encoding for Luciferase (Luc) under NFAT/AP1-dependent 
control. Our results are discussed in the hypothetical frame-
work on the development of adaptive NKG2C+ cells in response 
to HCMV.
MaTerials anD MeThODs
mabs and Flow cytometry analysis
Flow cytometry was performed using mAbs specific for the 
following surface molecules: anti-NKG2C-PE (clone 134591) 
R&D Systems (Minneapolis, MN, USA), anti-HLA-I-APC 
(clone HP-1F7) generated in our laboratory and conjugated by 
Immunostep (Salamanca, Spain). The following indirect antibod-
ies were used as purified or culture supernatants: anti-HLA-E 
(clone 3D12) provided by Dr. D. E. Geraghty (Fred Hutchinson 
Cancer Research Centre, Seattle, WA, USA), anti-CD3 (clone 
SpvT3B); anti-NKG2A (clone Z199), anti-NKG2D (clone 
BAT221), anti-NKp46 (clone Bab281), anti-NKp30 (clone AZ20), 
anti-DNAM1 (clone F22), anti-CD16 (KD1) provided by Dr. A. 
Moretta (University of Genova), and Dr. D. Pende (National 
Institute for Cancer Research, Genova); anti-LFA1 (clone TS/18), 
anti-ICAM1 (clone HU5/3) provided by Dr. F. Sánchez-Madrid 
(Hospital Univ. de la Princesa, Madrid); anti-KIR3DL1 (clone 
DX9) provided by Dr. L. Lanier (University of California San 
Francisco, CA, USA); anti-KIR2DL2/S2/L3 (clone CH-L) pro-
vided by Dr. S. Ferrini (National Institute for Cancer Research, 
Genova, Italy); anti-KIR3DL1/3DL2/2DS4/2DS5/2DS2/3DS1 
(clone 5.133), provided by Dr. M. Colonna (University of Saint 
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Louis, MO, USA). Anti-CD94 (clone HP-3B1), anti-ILT2 (LILRB1, 
LIR1) (clone HP-F1), anti-CD2 (clone MAR206), anti-KIR2DL1 
(clone HP-DM1), anti-KIR2DL1/2DS1/2DS3/2DS5 (clone 
HP-MA4), anti-KIR2DL5 (clone UP-R1), and anti-KIR2DL1/S1/
S4 (clone HP-3E4) were produced in our laboratory.
Briefly, cells were pretreated with human IgG (10 µg/ml) to 
block Fc receptors, incubated with individual NKR-specific 
mAbs for 30  min, washed, and further incubated with a sec-
ondary PE-tagged F(ab’)2 rabbit anti-mouse Ig (The Jackson 
Immunoresearch, West Grove PA, USA); anti-myc mAb (9E10, 
IgG1) was used as negative control. Data were acquired on 
FACSCalibur flow cytometer (BD Biosciences) and processed 
using FlowJo software (TreeStar, OR, USA).
cell lines and culture conditions
The Jurkat leukemia T cell line and its transfectants were grown 
in RPMI-1640 medium (Gibco, Grand Island, New York, NY, 
USA) supplemented with 10% heat-inactivated Fetal Bovine 
Serum (Gibco), 100 U/ml penicillin, and 100 µg/ml streptomy-
cin (Gibco), termed as complete medium. Jurkat-CD94+ cells 
were kindly provided by Dr. Lewis Lanier, obtained as previously 
described (37) and cultured in complete medium with G418 
(1 mg/ml) (InvivoGen, San Diego, CA, USA).
The 721.221 (.221) HLA-I-deficient EBV-transformed B 
lymphoblastoid cell line and its transfectant .221-AEH (kindly 
provided by Dr. D. E. Geraghty, Fred Hutchinson Cancer Research 
Centre, Seattle, WA, USA) were cultured in RPMI-1640 complete 
medium .221-AEH cells were generated by stable transfection of 
.221 cells with a construct in which the leader sequence of the 
HLA-E*0101 allele was replaced by that of HLA-A2 and were 
selected in the presence of 300 µg/ml hygromycin B (Invitrogen, 
Carlsbad, CA, USA) (38).
Synthetic leader sequence peptides from HLA-G 
(VMAPRTLFL) or the AD169 UL40 viral protein (VMAPRTLIL) 
were purchased from CRG-UPF proteomic core facility (Parc de 
Recerca Biomèdica de Barcelona, Spain). As described (39), to 
stabilize HLA-E surface expression, HLA-Ia-defective 721.221 
cells were incubated overnight with peptides (10 mM) at 26°C; 
HLA-E surface expression was monitored before and after incu-
bation with peptides by flow cytometry.
Human Fetal Foreskin Fibroblast (HFFF) cells provided 
by Prof. John Trowsdale (University of Cambridge, UK), and 
the human lung fibroblast cell line MRC-5 provided by Dr. A. 
Angulo, were maintained in Dulbecco modified essential medium 
(DMEM) (Gibco) supplemented with 10% FBS, penicillin, and 
streptomycin.
generation of Jurkat-nKg2c+ reporter 
cells
Jurkat-NKG2C+ cells were established using a retroviral expres-
sion system to stably express DAP12 and NKG2C proteins in 
Jurkat-CD94+ cells. DAP12 and NKG2C cDNA constructs 
were subcloned from pJFE14 expression vector to pBABE-puro 
retroviral vector using XbaI-EcoRI (DAP12) and BamHI-EcoRI 
(NKG2C) restriction sites. As described (40), the retroviral con-
structs were individually transfected using the non-modified 
polyethyleneimine reagent (PEI, Sigma-Aldrich, St. Louis, MO, 
USA) into the helper-virus free amphotropic producer cell line 
Phoenix-A, a derivative of the human embryonic kidney cell 
line 293T (provided by Dr. Ramon Gimeno, IMIM, Barcelona, 
Spain). At 48, 72, and 96  h post-transfection, supernatants 
containing retroviral particles of DAP12 and NKG2C were col-
lected, filtered with 45 µm filter (Millipore, Billerica, MA, USA), 
and centrifuged with Beckman SW28 rotor at 25,000  rpm for 
90 min at 4°C. Pelleted virus were resuspended in 1 ml of RPMI 
medium and used to transduce Jurkat-CD94+ cells. To this end, 
500,000 cells were plated (48 well/plates) in 1 ml mixed concen-
trated retroviral medium (0.5 ml DAP12 and 0.5 ml NKG2C) 
in the presence of 8  µg/ml polybrene (Sigma-Aldrich) and 
spinned for 90 min at 930 g. Cells were supplemented with fresh 
medium at 6 h post-transduction and selected with 1.5 µg/ml 
puromycin (Sigma-Aldrich) for 48 h; subsequently, cells positive 
for NKG2C surface expression were sorted (Influx Cell sorter, 
BD Bioscience), cloned by limiting dilution and expanded.
hcMV Preparations and infection of 
human Fetal Foreskin Fibroblasts (hFFF)
This work was carried out in an authorized UPF p2-level 
biohazard facility, in compliance with the official requirements 
for CMV manipulation. Stocks of concentrated HCMV strains 
AD169 and Towne, provided by Dr. A. Angulo, TB40/E, provided 
by Dr. C. Sinzger (Institute for Medical Virology, University of 
Tübingen), and two HCMV clinical isolates: UL1271 (41) and 
#119, provided by Dr. H. Hengel, were prepared as follows. 
Almost confluent MRC-5 fibroblasts were infected at low mul-
tiplicity of infection (MOI) and supernatants were recovered 
when maximum cytopathic effect was reached (7–10 days) fol-
lowed by clearing of cellular debris by centrifugation at 1,750 g 
for 10 min (42). Thereafter, the virus was concentrated for 3 h 
by centrifugation at 29,000 g at 15°C. Pelleted virus was resus-
pended in serum-free Dulbecco medium, stored at −80°C, and 
titrated by standard plaque assays.
Human fetal foreskin fibroblasts were seeded in 48-well plates 
2 days prior infection at 4 × 104 cells/well. Confluent cells were 
incubated alone (mock) or with different viral strains at MOI of 
10. After 2 h of absorption at 37°C, cells were washed twice with 
PBS and then fresh DMEM medium was added. Depending on 
the experimental design, HFFF cells were washed again at 24, 48, 
or 72 h postinfection. The infection rate was assessed by monitor-
ing expression of the IE1 protein by indirect immunofluorescence 
with mAb MAB810R (clone 8B1.2) (Millipore) and Alexa Fluor 
488-Labeled F(ab’)2 goat anti-mouse secondary (Invitrogen, 
Carlsbad, CA, USA). Alternatively, infected cells were indirectly 
identified assessing down-modulationof surface HLA-I expres-
sion at 72 h postinfection.
Preparation and activation  
of cD94-nKg2c+ reporter cells
Human cytomegalovirus-infected HFFFs were cocultured with 
Jurkat-NKG2C+ cells previously transfected with a reporter 
plasmid encoding Luciferase (Luc) under the control of NFAT/
AP1 promoter (3X NFAT/AP1-Luc) generated as described (43) 
FigUre 1 | Phenotypic characterization of Jurkat-NKG2C+ reporter cells. 
(a) Jurkat-CD94+ cells were transduced with retroviral particles carrying the 
sequences encoding for NKG2C and DAP12 as described in Section 
“Materials and Methods.” After sorting, expansion, and limiting dilution, clone 97, 
which expressed high levels of the CD94/NKG2C heterodimer was selected. 
(B) Jurkat-NKG2C+ cells were stained for the indicated receptors and 
analyzed by flow cytometry. KIRMIX corresponds to a mixture of the following 
monoclonal antibodies: HP-MA4 (KIR2DL1/2DS1/2DS3/2DS5), CHL 
(KIR2DL2/2DL3/2DS2), 5.133 (KIR3DL1/3DL2/2DS4/2DS5/2DS2/3DS1), 
DX9 (KIR3DL1), UP-R1 (KIR2DL5). Gray histograms correspond to the 
isotype control.
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and provided by Dr. Jose Aramburu (Universitat Pompeu Fabra, 
Barcelona, Spain). Transfection of Jurkat cells was carried out using 
the Neon Transfection System (Thermo Fisher Scientific, Waltham, 
MA, USA) following the protocol provided by the manufacturer. 
Luc-transfected Jurkat cells were cocultured with the different 
targets for 18–24 h. After coculture, cells were collected, lysed, and 
Luc activity was measured using Promega Luciferase Assay system 
(Promega, Madison, WI, USA). The data were normalized refer-
ring the specific luminescence counts to those of non-treated (NT) 
Jurkat-NKG2C+ cells and are represented as fold-change induc-
tion. Stimulation of Jurkat with plate-bound anti-CD3, -CD94, 
-NKG2C, or co-culture with 721.221 and .221-AEH cells were 
used as controls. To verify the involvement of NFAT/AP1 in the 
reporter activation, experiments were carried out in the presence 
of 1 µM FK506 calcineurin inhibitor (Sigma-Aldrich), pretreating 
Jurkat-NKG2C+ cells with the drug for 2 h. For antibody-blocking 
assays, Jurkat-NKG2C+ cells or infected HFFF cells were, respec-
tively, preincubated for 2 h with anti-NKG2C (clone 134522, R&D 
Systems) or anti-HLA-E (clone 3D12) mAbs (5 µg/ml) prior to 
coculture; anti-CD94 F(ab’)2 fragments obtained from the HP-3B1 
clone (37) were employed in some experiments.
statistical analysis
Jurkat-NKG2C+ cell activation, assessed by induction of Luc 
activity in response to control stimuli (i.e., anti-NKG2C or .221-
AEH cells) in different experiments (n = 15), was verified to follow 
a normal distribution applying the conventional Shapiro–Wilk 
test. Statistical analysis of the results was carried out applying the 
Student’s t-test.
resUlTs
generation and Phenotypic 
characterization of a human  
cD94/nKg2c+ reporter T cell line
To study the role of the CD94/NKG2C NKR in recognition of 
HCMV-infected cells, a reporter cell system was developed 
expressing the receptor segregated from other NKR. For this 
purpose, NKG2C and DAP12 were stably transduced in an 
available CD94-transfected human Jurkat leukemia T  cell line. 
Jurkat-NKG2C+ cells were sorted and cloned by limiting dilution 
assessing the expression of adhesion molecules and NKR. A clone 
(97), which expressed CD94/NKG2C was selected (Figure 1A). 
These cells had downregulated CD3, displayed adhesion/co-
stimulatory molecules (i.e., LFA-1, CD2, ICAM-1, and DNAM-
1), but lacked activating (i.e., NKG2D, NKp46, NKp44, NKp30, 
CD16, aKIR) and inhibitory (i.e., iKIR, NKG2A, TIGIT, ILT2) 
NKR (Figure 1B). The marginal expression of ILT2 was particu-
larly important as this HLA-I specific inhibitory receptor, which 
interacts with the UL18 HCMV molecules, was detectable in the 
parental Jurkat-CD94+ cells (not shown).
specific recognition of hla-e by Jurkat-
nKg2c+ reporter cells
In order to detect signaling by the CD94/NKG2C-DAP12 com-
plex, Jurkat-NKG2C+ cells were transiently transfected with 
a plasmid encoding for Luciferase (Luc) under the control of 
NFAT/AP1-dependent promoter. Engagement of the receptor 
by solid-phase bound CD94- or NKG2C-specific mAbs trig-
gered Luc expression (Figure  2A). Of note, a slightly higher 
background in Jurkat-NKG2C+ cells compared to the parental 
cell line suggested that the low constitutive HLA-E expression 
in Jurkat-NKG2C+ cells promoted a limited self-activation of 
the reporter (Figure S1 in Supplementary material). However, 
coculture of Jurkat-NKG2C+ cells with the .221-AEH cell line, 
FigUre 2 | Specific engagement of the CD94/NKG2C receptor by HLA-E activates the Jurkat-NKG2C+ reporter. (a) Jurkat-NKG2C+ cells were electroporated 
with 3× NFAT/AP1-Luc plasmid, followed by stimulation with: (a) anti-NKG2C or anti-CD94 monoclonal antibodies (mAbs) pre-adsorbed to culture plates or (b) with 
.221 or .221-AEH cells. After 18–24 h, cells were collected, lysed, and Luc activity was measured. Blocking experiments were carried out pretreating .221 and 
.221-AEH cells with anti-HLA-E 3D12 mAb (gray bars) or Jurkat-NKG2C+ cells with anti-NKG2C mAb (white bars); NT, not treated. Data correspond to three 
independent experiments (mean ± SD). (B) HLA-E expression by .221 and .221-AEH was assessed prior to coculture with Jurkat-NKG2C+ cells (gray histograms 
represent the isotype control). Statistically significant differences are indicated (**p < 0.01).
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which displays HLA-E in the absence of classical HLA-I, induced 
Luc expression and the response was specifically antagonized 
by soluble NKG2C- and HLA-E-specific mAbs (Figures 2A,B). 
Similar results were obtained stimulating Jurkat-NKG2C+ cells 
with the .221 cell line preincubated with synthetic HLA-I leader 
sequence peptides, known to stabilize surface HLA-E expres-
sion (Figures  3A,B). These results validated the sensitivity 
and specificity of the reporter system to detect CD94/NKG2C 
receptor–ligand interaction.
response of Jurkat-nKg2c+ reporter 
cells to Fibroblasts infected by hcMV 
laboratory strains
On that ground, experiments were carried out incubating Jurkat-
NKG2C+ cells with HFFF, infected at different time-points 
(24–72 h) with HCMV laboratory strains (AD169 and Towne). 
As compared to positive controls stimulated with anti-NKG2C 
mAb or .221-AEH cells, no differences were perceived compar-
ing Luc expression in Jurkat-NKG2C+ cocultured either with 
mock- or HCMV-infected HFFF (Figure  4A); similar results 
were obtained incubating the reporter with MRC5 fibroblasts 
(not shown). Total HLA-I expression was downregulated in 
cells infected by both HCMV strains. By contrast, HLA-E was 
preserved by AD169, which displays a canonical UL40 leader 
peptide (VMAPRTLIL) binding to the HLA class Ib molecule, 
but was lost in Towne-infected cells (Figure 4B). As reported 
(44) and according to the annotated GenBank sequences, this 
HCMV strain contains a deletion spanning the UL40 leader 
sequence. These results point out that the undetectable response 
of Jurkat-NKG2C+ to fibroblasts infected by laboratory 
strains was unrelated to their ability to sustain surface HLA-E 
expression.
response of Jurkat-nKg2c+ reporter 
cells to Fibroblasts infected by hcMV 
clinical isolates
TB40/E HCMV strain retains the ability to replicate in 
endothelial and myelomonocytic cells, differing from AD169 
and Towne (45). Moreover, it is well established that HCMV 
clinical isolates substantially diverge from laboratory strains, 
rapidly undergoing important genomic changes upon in vitro 
passage, as reviewed in Ref. (46). Thus, additional experi-
ments were carried out coculturing Jurkat-NKG2C+ cells with 
HFFF infected with TB40/E, which encodes for a UL40 leader 
peptide variant unable to preserve HLA-E surface expres-
sion (VVAPRTLIL) (25), or with two HCMV clinical isolates 
FigUre 3 | Activation of Jurkat-NKG2C+ cells by HLA-E loaded with the canonical human cytomegalovirus UL40 leader sequence-derived synthetic peptide on 
721.221 cells. (a) As described for Figure 2, Jurkat-NKG2C+ cells were: (a) untreated (NT), (b) stimulated with plate coated anti-NKG2C, or (c) cocultured with the 
.221 or .221-AEH cells (black bars). In parallel, the response of Jurkat-NKG2C+ cells was assessed coculturing them with .221 cells preincubated at 26°C overnight 
with synthetic peptides corresponding to HLA-G (VMAPRTLFL) and AD169 UL40 (VMAPRTLIL) leader sequences, reported to stabilize HLA-E expression (gray 
bars). Data correspond to three independent experiments (mean ± SD). (B) HLA-E expression by .221-AEH and .221 cells preincubated with peptides prior to 
coculture with Jurkat-NKG2C+ cells; gray histograms represent the isotype control. Statistically significant differences are indicated (**p < 0.01).
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(#UL1271 and #119), which share the canonical UL40-nonamer 
and preserved HLA-E expression (Figures 5A,B). Remarkably, 
a specific response of the reporter was detected upon infection 
with these viruses, which appeared greater for #119 and gradu-
ally increased along postinfection time. Yet, controls indicated 
that Luc expression in response to HFFF infected with HCMV 
clinical isolates was not inhibited by pretreatment with anti-
NKG2C or -HLA-E mAbs (Figures 6A,B); similar results were 
obtained with anti-CD94 F(ab′)2 fragments (data not shown), 
ruling out the potential influence of an overlapping agonistic 
effect mediated by anti-NKG2C bound to virus-encoded FcR. 
Moreover, the effect was also induced in CD94+ and wild-type 
Jurkat cells, which lacked NKG2C, unequivocally revealing that 
reporter activation was independent of this NKR (Figure 6C); 
similar results were obtained with TB40/E-infected cells (data 
not shown). As this response was dominant, the possibility that 
it might eventually mask a subtle involvement of CD94/NKG2C 
cannot be entirely ruled out.
DiscUssiOn
A number of observations indirectly support the hypothesis that 
a specific and direct interaction of CD94/NKG2C with infected 
cells contributes to drive the adaptive NK  cell response; yet, 
molecular evidence remains thus far elusive (10). To explore 
the presence of putative ligand(s) for CD94/NKG2C in HCMV-
infected cells, the receptor was stably expressed along with 
DAP12 in the human Jurkat leukemia cell line, transiently trans-
fected with an NFAT/AP1-dependent Luc-encoding reporter. 
The rationale for using a human parental cell line was based 
on our previous experience with heterologous CD94/NKG2C+ 
rat basophilic leukemia cells (RBL), which failed to respond to 
receptor engagement by HLA-E+ .221-AEH cells (not shown). 
A Jurkat-NKG2C+ clone that shared with NK cells key adhesion 
receptors (i.e., LFA-1, CD2, and DNAM1) but lacked inhibitory 
NKR, was selected.
The possibility that constitutive HLA-E expression by Jurkat-
NKG2C+ cells might promote self-activation of the reporter, 
potentially impairing its responsiveness to external stimuli, was 
beforehand considered a potential drawback. Yet, Luc expression 
in Jurkat-NKG2C+ cells was induced following stimulation with 
CD94 or NKG2C-specific mAbs. Importantly, reporter activa-
tion was detectable upon interaction with HLA-E+  .221-AEH 
cells, as well as with .221 cells incubated with synthetic peptides 
which stabilized surface expression of endogenous HLA-E; in 
these settings, inhibition by anti-NKG2C and -HLA-E mAbs 
supported specific receptor-ligand engagement. By contrast, 
reporter activation was undetectable upon interaction of 
FigUre 4 | Cells infected with AD169 or Towne human cytomegalovirus (HCMV) strains do not activate the Jurkat-NKG2C+ reporter independently of HLA-E 
expression. (a) HFFF cells infected with AD169 or Towne HCMV strains (multiplicity of infection = 10) were cocultured at 24, 48, and 72 h postinfection with 
Jurkat-NKG2C+ cells electroporated with the reporter plasmid. The average infection rate for each experiment was >50%. As a control, reporter activation following 
CD94/NKG2C receptor engagement by specific monoclonal antibodies or HLA-E was assessed in parallel, as described in Figure 2. Data correspond to three 
independent experiments (mean ± SD). (B) Total HLA-I and HLA-E expression at 72 h postinfection in mock-treated and HCMV-infected HFFF cells. Statistically 
significant differences are indicated (**p < 0.01).
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Jurkat-NKG2C+ cells with HFFF or MRC5 fibroblasts following 
infection with common HCMV laboratory strains (i.e., AD169, 
Towne), regardless of their ability to preserve surface HLA-E 
expression in infected cells.
Among variables that may potentially condition the 
expression of CD94/NKG2C ligand(s) by HCMV-infected 
cells, genomic differences between viral strains and changes 
associated to in  vitro passage of the virus were considered 
potentially important. In fact, cells infected with two different 
clinical isolates and, to a lesser degree, with the endotheliotropic 
TB40/E strain, triggered Jurkat-NKG2C+ activation. Yet, this 
response was not inhibited by NKG2C- nor HLA-E-specific 
blocking mAbs and, furthermore, was independent of CD94/
NKG2C expression. Experiments were carried out to explore the 
molecular basis of this dominant effect, which might potentially 
mask CD94/NKG2C-specific signaling. Pretreatment of Jurkat-
NKG2C+ with a calcineurin inhibitor (FK506) hampered Luc 
expression triggered by anti NKG2C mAb or .221-AEH cells, but 
did not prevent the response of Jurkat-NKG2C+ cells to HCMV 
clinical isolates (data not shown), pointing out that a non- 
conventional activation of the reporter plasmid was induced 
under these experimental conditions. Further studies are required 
FigUre 5 | Activation of Jurkat-NKG2C+ reporter cells by HFFF infected with human cytomegalovirus TB40/E or clinical isolates is independent of HLA-E 
expression. (a) The Jurkat-NKG2C+ reporter was cocultured with HFFF cells at different time-points (24–72 h) postinfection with TB40/E or two different clinical 
isolates (UL1271 and #119) (multiplicity of infection = 10). Data correspond to three independent experiments (mean ± SD). Average infection rate for each 
experiment was >50%. (B) Total HLA-I and HLA-E surface expression was monitored at 72 h postinfection. Statistically significant differences are indicated 
(*p < 0.05; **p < 0.01).
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to assess the possibility of controlling this drawback, eventually 
re-designing the system.
NKG2C+ NK  cells were reported to be activated upon 
interaction with primary aortic endothelial cells infected by the 
VHL/E HCMV strain (47); nevertheless, no data supporting an 
involvement of the receptor (e.g., blocking with anti-CD94 or 
-NKG2C mAbs) were provided. In our hands, Jurkat-NKG2C+ 
did not detectably respond to HCMV-infected MRC5 fibro-
blasts nor to human umbilical vein endothelial cells. Yet, the 
possibility that expression of putative CD94/NKG2C ligands 
might vary depending on the infected cell lineage is not ruled 
out.
Our observations should be discussed in the framework 
of previous indications supporting a CD94/NKG2C recep-
tor interaction with infected cells. In this regard, NKG2C+ 
NK  cells were shown to undergo in  vitro expansion upon 
coculture with AD169 or Towne-infected fibroblasts (22, 23). 
The effect was dependent on cytokines (i.e., IL-12, IL-15) and 
was prevented by blocking anti-CD94, -NKG2C, or -HLA-E 
mAbs. The response was observed only in samples from some 
HCMV+ blood donors displaying baseline NKG2Cbright NK cell 
expansions, indicating that these experimental conditions 
promoted their proliferation, but did not strictly reproduce 
the differentiation process induced in vivo by primary HCMV 
infection. Of note, in  vitro expansion was prevented upon 
infection by an HCMV BACmid mutant lacking the whole set 
of viral genes (i.e., US2-US11), which target HLA-I molecules, 
thus preserving their expression in infected cells (22). These 
experiments were interpreted as an indication of a relatively 
weak stimulation via CD94/NKG2C that was overridden by 
inhibitory KIR-HLA-I interactions which, by contrast, did not 
impair CD16-triggered NK cell effector functions against cells 
infected by the same virus (28).
On the other hand, a relation of NKG2C gene copy number 
with the magnitude of NKG2C+ NK cell expansion has been 
reported in HCMV+ healthy blood donors, in children with 
congenital infection and in renal transplant recipients (9, 14, 
32, 48). Moreover, CD94/NKG2C surface expression levels and 
FigUre 6 | Jurkat-NKG2C+ activation by cells infected with human cytomegalovirus (HCMV) clinical isolates is independent of the CD94/NKG2C receptor.  
(a) Response of Jurkat-NKG2C+ reporter to HFFF infected by HCMV clinical isolates or .221-AEH cells preincubated with the 3D12 anti-HLA-E monoclonal 
antibody (mAb) (5 µg/ml). (B) The blocking effect of an anti-NKG2C mAb (clone MAB1381) (5 µg/ml) on the response of Jurkat-NKG2C+ cells to stimulation with 
either plate-bound anti-NKG2C mAb, .221-AEH cells or HFFF infected by HCMV clinical isolates (white bars) was assessed in parallel. Data correspond to three 
independent experiments (mean ± SD); the average infection rate for each experiment was >50%. (c) Jurkat-NKG2C+ (black bars), Jurkat-CD94+ (gray bars), and 
wild-type Jurkat (WT) (white bars) were stimulated with 1 µg/ml of plate-bound anti-CD3, -NKG2C, -CD94 mAbs, or cocultured with .221 or .221-AEH cells 
(negative and positive controls). Confluent HFFF cells infected with UL1271 and #119 clinical isolates (multiplicity of infection = 10) for 72 h were cocultured with the 
different Jurkat cell lines (NKG2C+, CD94+, and WT) previously electroporated with the reporter plasmid. Data correspond to three independent experiments 
(mean ± SD); the average infection rate for each experiment was >50%. Statistically significant differences are indicated (*p < 0.05; **p < 0.01).
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activation upon engagement by HLA-E were also greater in 
NKG2Cbright NK cells from NKG2C+/+ than NKG2C+/del individu-
als (9). These data supported that subtle differences in CD94/
NKG2C surface density may quantitatively influence adaptive 
NK  cell differentiation/activation in response to HCMV, thus 
providing another indirect indication for a relatively low avidity 
of the hypothetical receptor–ligand interaction. The increased 
surface expression of CD94/NKG2C in differentiated adaptive 
NK cells (NKG2Cbright) from HCMV+ subjects as compared to 
the profile detected in non-infected individuals (NKG2Cdim) 
is also in line with this view. Of note, a limited affinity and/or 
reduced expression levels of the putative CD94/NKG2C ligand 
in infected cells may presumably render this pathway particu-
larly sensitive to viral immune evasion mechanisms, eventually 
accounting for the undetectable activation of NKG2C+ NK cell 
effector functions and of Jurkat-NKG2C+ cells, in that case, 
independently of HLA-specific inhibitory receptors.
Despite the negative results obtained with the reporter 
system, the existence of specific ligand(s) for CD94/NKG2C 
in HCMV-infected cells still remains a plausible hypothesis, 
compatible with the involvement of a viral glycoprotein or/and 
an HLA-E-peptide complex. The latter option is suggested by 
the blocking effect of an anti-HLA-E mAb in the expansion of 
NKG2C+ NK cells cocultured with infected fibroblasts (23). A 
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first candidate to be considered is the UL40 leader sequence-
derived peptide reported to promote HLA-E expression in 
HCMV-infected cells by a mechanism refractory to the viral US6 
TAP inhibitor (34) and favored by the intrinsic HLA-E resistance 
to other viral molecules targeting HLA-I (49). UL40-dependent 
HLA-E expression in infected cells was shown to inhibit NK cell 
activation by engagement of the CD94/NKG2A inhibitory 
receptor, presumably contributing to immune evasion (34). 
The canonical UL40-derived nonamer (VMAPRTLIL) binding 
to HLA-E is identical to that displayed by some HLA-I leader 
sequences, predictably promoting a low affinity interaction with 
CD94/NKG2C (50). Heatley et al. (51) compared the ability of a 
panel of UL40-nonamer variants to stabilize HLA-E in RMA-S 
cells, assessing the interaction of the corresponding HLA-E/pep-
tide complexes with CD94/NKG2A or CD94/NKG2C by surface 
plasmon resonance assays, as well as their recognition by NK cell 
subsets, respectively, displaying these NKR. Of note, quantitative 
differences in the interaction of distinct HLA-E-peptide com-
plexes were noticed, but none appeared preferentially recognized 
by CD94/NKG2C.
It is conceivable that HLA-E expression by HCMV-infected 
cells, in which HLA-I ligands for inhibitory KIRs are downregu-
lated, might promote specific activation of NKG2C+ NKG2A- 
NK cells. Supporting this hypothesis, Jurkat-NKG2C+ cells were 
activated by .221 cells displaying HLA-E bound to the synthetic 
AD169 UL40-derived peptide (VMAPRTLIL), shared by some 
HLA-I alleles. Nevertheless, no reporter response was perceived 
following interaction with AD169-infected cells expressing HLA-
E, pointing out to the influence of additional factors, and indicat-
ing that experimental approaches based on loading target cells 
with synthetic peptides provide valuable information but do not 
precisely reflect the complexity of HCMV infection. A putative 
role of UL40 in NKG2C+ NK cell expansion, detected following 
coculture with AD169-infected cells, was addressed employing 
a UL40 deletion mutant generated in an AD169 BACmid (HB5) 
(22, 23). In this setting, cells infected with ΔUL40 HB5 retained 
the ability to promote in vitro expansion of NKG2C+ NK cells; 
however, a caveat for interpreting these experiments is the gene 
deletion encompassing US2-US6 introduced for the generation 
of the HB5 BACmid. In fact, HCMV impairs surface expression 
of HLA-I molecules but not their biosynthesis and, therefore, 
endogenous HLA-I leader sequences in the absence of US6 
may be presented by HLA-E in HB5-infected cells, eventually 
competing with the UL40-derived nonamer, or even replacing 
it in ΔUL40 HB5-infected HFFF. On the other hand, NKG2C+ 
NK cell expansions detected in cocultures with Towne-infected 
fibroblasts (22) may indirectly provide a case against the involve-
ment of HLA-E expression, which was downregulated consistent 
with the existence of a genomic deletion spanning the UL40 
leader sequence of this HCMV strain (44). Of note, no relation 
of the HLA-E dimorphism with the expansion of NKG2C+ cells 
was noticed in previous studies (7, 9).
In summary, molecular evidence supporting that a specific 
interaction of CD94/NKG2C with infected cells drives the 
adaptive NK  cell response to HCMV remains elusive, leaving 
unanswered key interrelated questions, particularly, the cellular 
mechanisms underlying the stable expansion of NKG2Cbright 
NK  cells and the basis for the wide variability of this effect in 
HCMV+ individuals. Observations in immunocompromised 
patients suggested that this pattern of response may compensate 
an inefficient T-cell-mediated control of the primary infection, 
eventually determined in healthy individuals by viral/host genetic 
factors as well as by other circumstantial variables (e.g., age at 
infection, viral load, etc.).
We hypothesize that primary HCMV infection promotes 
the differentiation, proliferation, and survival of a pool of 
progenitors, possibly stemming from NKG2Cdim NKG2A- 
NK cells present in seronegative individuals. Increased surface 
expression of CD94/NKG2C presumably constitutes a key 
early event, facilitating activation of this NK cell subset upon 
interaction with low-avidity ligand(s) displayed by infected 
cells. Such NKG2C-driven selection is dependent on cytokines 
required for adaptive NK  cell differentiation/expansion and 
may be tuned by specific KIR-HLA-I interactions, consistent 
with the oligoclonal KIR expression profile of adaptive NK cells 
(8, 52). Following a contraction phase after viral replication 
is controlled, a pool of long-lived NKG2Cbright NK  cells with 
clonal expansion potential survive, and homeostatic prolifera-
tion contributes to their persistent increased numbers in the 
circulation. The process is reminiscent of the generation of 
memory cytotoxic T lymphocytes as proposed for the response 
of Ly49H in mice (53); in fact, responsiveness of differentiated 
NKG2Cbright NK  cells to cytokines (e.g., IL-15, IL-2) becomes 
dependent on signaling by activating NKR (e.g., NKG2C or 
CD16). HCMV reactivation/reinfection as well as other infec-
tious pathogens may boost antibody- and cytokine-dependent 
activation of adaptive NK  cells, leading to their progressive 
acquisition of late differentiation features (e.g., FcRγ down-
regulation). Further efforts are warranted to understand how 
HCMV infection resets the NK-cell compartment homeostasis 
in some individuals, and the implications that such persistent 
reconfiguration of the NK cell compartment may have in the 
development of the immune response under different patho-
logical conditions.
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